Literature DB >> 14506929

Concentrations of interferon-gamma-induced protein-10 (IP-10), an antiangiogenic substance, are decreased in peritoneal fluid of women with advanced endometriosis.

Osamu Yoshino1, Yutaka Osuga, Kaori Koga, Yasushi Hirota, Osamu Tsutsumi, Tetsu Yano, Yutaka Morita, Mikio Momoeda, Toshihiro Fujiwara, Koji Kugu, Yuji Taketani.   

Abstract

PROBLEM: To assess whether interferon-gamma-induced protein-10 (IP-10), a chemokine that has antiangiogenic activities, may be involved in the pathogenesis of endometriosis. METHOD OF STUDY: A total of 120 patients undergoing laparoscopy for pain and/or infertility were recruited, and peritoneal fluid (PF) and bone marrow derived cells in PF were collected. Concentrations of IP-10 in PF were measured with a specific enzyme-linked immunosorbent assay. Expression of IP-10 and IP-10 receptor, CXCR3, in bone marrow derived cells in PF, peritoneum and endometriotic cells was analyzed by reverse transcription-polymerase chain reaction.
RESULTS: All of the PF samples examined contained detectable concentrations of IP-10. In women with advanced stages of endometriosis, IP-10 concentrations in PF were significantly lower than those of women in early stages (P = 0.02). The IP-10 concentrations in women with advanced endometriosis also appeared to be lower than those without endometriosis although the difference was statistically marginal (P = 0.06). The expression of both IP-10 and CXCR3 was clearly detected in the bone marrow derived cells in PF, peritoneum and endometriotic stromal cells.
CONCLUSIONS: Decreased concentrations of IP-10 in PF from women with advanced stages of endometriosis may imply that the peritoneal environment of these women is permissive to the development of the disease by enhancing angiogenesis and/or modulating inflammatory/immunological responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14506929     DOI: 10.1034/j.1600-0897.2003.00037.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  8 in total

1.  Behavior of tumor necrosis factor-α and tumor necrosis factor receptor 1/tumor necrosis factor receptor 2 system in mononuclear cells recovered from peritoneal fluid of women with endometriosis at different stages.

Authors:  Francesca M Salmeri; Antonio S Laganà; Vincenza Sofo; Onofrio Triolo; Emanuele Sturlese; Giovanni Retto; Alfonsa Pizzo; Angela D'Ascola; Salvatore Campo
Journal:  Reprod Sci       Date:  2014-05-20       Impact factor: 3.060

2.  IP-10 blocks vascular endothelial growth factor-induced endothelial cell motility and tube formation via inhibition of calpain.

Authors:  Richard J Bodnar; Cecelia C Yates; Alan Wells
Journal:  Circ Res       Date:  2006-02-16       Impact factor: 17.367

Review 3.  Current concepts of the pathogenesis of endometriosis.

Authors:  Yutaka Osuga
Journal:  Reprod Med Biol       Date:  2009-08-26

Review 4.  Implications of immune dysfunction on endometriosis associated infertility.

Authors:  Jessica E Miller; Soo Hyun Ahn; Stephany P Monsanto; Kasra Khalaj; Madhuri Koti; Chandrakant Tayade
Journal:  Oncotarget       Date:  2017-01-24

Review 5.  Ethiopathogenic mechanisms of endometriosis-related infertility.

Authors:  Michele Gomes Da Broi; Rui Alberto Ferriani; Paula Andrea Navarro
Journal:  JBRA Assist Reprod       Date:  2019-08-22

6.  Immunological microenvironment alterations in follicles of women with proven severe endometriosis undergoing in vitro fertilization.

Authors:  Xiao-Dan Mao; Chen-Yu Hu; Meng-Chu Zhu; Hui-Lin Ou; Yu-Li Qian
Journal:  Mol Biol Rep       Date:  2019-09-10       Impact factor: 2.316

7.  Angiogenesis and endometriosis.

Authors:  Ana Luiza L Rocha; Fernando M Reis; Robert N Taylor
Journal:  Obstet Gynecol Int       Date:  2013-05-26

8.  Expression of IP-10 related to angiogenesis in uterine cervical cancers.

Authors:  E Sato; J Fujimoto; H Toyoki; H Sakaguchi; S M Alam; I Jahan; T Tamaya
Journal:  Br J Cancer       Date:  2007-05-15       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.